ArticleOncoTargets and therapy2017
Serpin peptidase inhibitor, clade A member 3 (SERPINA3), is overexpressed in glioma and associated with poor prognosis in glioma patients.
Article in OncoTargets and therapy, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 36 citations in OpenAlex.
- Dynamic release of extracellular particles after opening of the blood-brain barrier predicts glioblastoma susceptibility to paclitaxel.Nature communications · 2025Article
- Prognostic Value of MCM3AP-AS1 in Glioma and its Regulatory Effect on Tumor Progression.Neurochemical research · 2025Article
- PARD6A promotes lung adenocarcinoma cell proliferation and invasion through Serpina3.Cancer gene therapy · 2024Article
- Tumor-infiltrating CD8Heliyon · 2024Article
- Immunohistochemical Expression of the SERPINA3 Protein in Uterine Fibroids.Current pharmaceutical biotechnology · 2024Article
- SERPINA3: Stimulator or Inhibitor of Pathological Changes.Biomedicines · 2023Review
- Differences in the Expression Patterns ofCancers · 2022Article
- Highly expressed of SERPINA3 indicated poor prognosis and involved in immune suppression in glioma.Immunity, inflammation and disease · 2021Article
- Circulating SERPINA3 improves prognostic stratification in patients with a de novo or worsened heart failure.ESC heart failure · 2021Article
- Review
- Alpha 1-antichymotrypsin contributes to stem cell characteristics and enhances tumorigenicity of glioblastoma.Neuro-oncology · 2021Article
- Differential gene expression in peritumoral brain zone of glioblastoma: role of SERPINA3 in promoting invasion, stemness and radioresistance of glioma cells and association with poor patient prognosis and recurrence.Journal of neuro-oncology · 2021Article
- Prognostic Value of Tumor Mutational Burden Related to Immune Infiltration in Cervical Squamous Cell Carcinoma.Frontiers in medicine · 2021Article
- Involvement of Extracellular Vesicles in Vascular-Related Functions in Cancer Progression and Metastasis.International journal of molecular sciences · 2019Review
- Swainsonine represses glioma cell proliferation, migration and invasion by reduction of miR-92a expression.BMC cancer · 2019Article
- SERPINA3 Silencing Inhibits the Migration, Invasion, and Liver Metastasis of Colon Cancer Cells.Digestive diseases and sciences · 2018Article
- Identification of blood biomarkers in glioblastoma by SWATH mass spectrometry and quantitative targeted absolute proteomics.PloS one · 2018Article
- Differential overexpression of SERPINA3 in human prion diseases.Scientific reports · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Glioma is the most common and aggressive human primary tumor in the central nervous system. Despite present clinical advancements, median survival time remains poor in this malignant tumor. Serpin peptidase inhibitor, clade A member 3 (SERPINA3), is a member of the serpin superfamily of protease inhibitors. Its aberrant expression has been observed in various tumors. However, its clinical significance and biological function in glioma remain unclear, especially for the prognosis of glioma patients. In this study, we investigated SERPINA3 expression in glioma tissue samples and its significance in predicting the prognosis of glioma patients. SERPINA3 protein expression was studied by immunohistochemistry, while real-time polymerase chain reaction was used to study SERPINA3 mRNA expression. We found that SERPINA3 was upregulated in glioma tissue at both mRNA and protein levels, compared with noncancerous brain tissues. We also found that high SERPINA3 expression in glioma tissues correlated significantly with advanced World Health Organization grade. Univariate and multivariate analyses revealed that high SERPINA3 expression was an independent prognostic factor for poor overall survival of glioma patients. Moreover, our findings were further validated by online Oncomine database. Taken together, our results suggest that SERPINA3 plays an oncogenic role in glioma progression and provide an insight into the application of SERPINA3 as a novel predictor of clinical outcomes and a potential biomarker of glioma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.